B Lineage Cells and IgE in Allergic Rhinitis and CRSwNP and the Role of Omalizumab Treatment

被引:10
|
作者
Bai, Junqin [1 ]
Tan, Bruce K. [1 ,2 ,3 ]
机构
[1] Northwestern Univ Feinberg, Dept Otolaryngol, Sch Med, Chicago, IL USA
[2] Northwestern Univ Feinberg, Dept Med, Div Allergy & Immunol, Sch Med, Chicago, IL USA
[3] Northwestern Univ Feinberg, Dept Otolaryngol Head & Neck Surg, Sch Med, 676 N St Clair St,Suite 1325, Chicago, IL 60611 USA
关键词
allergic rhinitis; chronic rhinosinusitis with nasal polyps; type; 2; inflammation; B cell; plasma cell; germinal center; extrafollicular; autoantibody; immunoglobulin E; omalizumab; FC-EPSILON-RI; CHRONIC RHINOSINUSITIS; STAPHYLOCOCCUS-AUREUS; NASAL POLYPS; AIRWAY INFLAMMATION; ASTHMA; ANTIBODY; SUPERANTIGENS; ENTEROTOXINS; RESPONSES;
D O I
10.1177/19458924221147770
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
BackgroundAllergic rhinitis (AR) and chronic rhinosinusitis (CRS) are two prevalent nasal diseases where both type 2 inflammation and immunoglobulin E (IgE) may play important roles. Although they can exist independently or comorbidly, subtle but important differences exist in immunopathogenesis. ObjectiveTo summarize current knowledge of pathophysiological roles of B lineage cells and IgE in AR and CRS with nasal polyps (CRSwNP). MethodsSearched PubMed database, reviewed AR and CRSwNP-related literature, and discussed disease diagnosis, comorbidity, epidemiology, pathophysiology, and treatment. Similarities and differences in B-cell biology and IgE are compared in the 2 conditions. ResultsBoth AR and CRSwNP have evidence for pathological type 2 inflammation, B-cell activation and differentiation, and IgE production. However, distinctions exist in the clinical and serological profiles at diagnosis, as well as treatments utilized. B-cell activation in AR may more frequently be regulated in the germinal center of lymphoid follicles, whereas CRSwNP may occur via extrafollicular pathways although controversies remain in these initial activating events. Oligoclonal and antigen-specific IgE maybe predominate in AR, but polyclonal and antigen-nonspecific IgE may predominate in CRSwNP. Omalizumab has been shown efficacious in treating both AR and CRSwNP in multiple clinical trials but is the only Food and Drug Administration-approved anti-IgE biologic to treat CRSwNP or allergic asthma. Staphylococcus aureus frequently colonizes the nasal airway and has the ability to activate type two responses including B-cell responses although the extent to which it modulates AR and CRSwNP disease severity is being investigated. ConclusionThis review highlights current knowledge of the roles of B cells and IgE in the pathogenesis of AR and CRSwNP and a small comparison between the 2 diseases. More systemic studies should be done to elevate the understanding of these diseases and their treatment.
引用
收藏
页码:182 / 192
页数:11
相关论文
共 50 条
  • [1] Omalizumab for treatment of allergic rhinitis
    Vashisht, Priyanka
    Casale, Thomas
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (06) : 933 - 945
  • [2] Anti-IgE treatment in allergic rhinitis
    Muluk, Nuray Bayar
    Bafaqeeh, Sameer Ali
    Cingi, Cemal
    INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2019, 127
  • [3] Anti-IgE for the treatment of allergic rhinitis - and eventually nasal polyps?
    Verbruggen, K.
    Van Cawenberge, P.
    Bachert, C.
    ALLERGOLOGIE, 2007, 30 (09) : 338 - 353
  • [4] Anti-IgE for the Treatment of Allergic Rhinitis and Eventually Nasal Polyps?
    Verbruggen, Katia
    Van Cauwenberge, Paul
    Bachert, Claus
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2009, 148 (02) : 87 - 98
  • [5] Omalizumab and the treatment of allergic rhinitis
    Michael A. Kaliner
    Current Allergy and Asthma Reports, 2004, 4 : 237 - 244
  • [6] Anti-IgE: A treatment option in allergic rhinitis?
    Pfaar, O.
    Gehrt, F.
    Li, H.
    Rudhart, S. A.
    Nastev, A.
    Stuck, B. A.
    Hoch, S.
    ALLERGOLOGIE, 2021, 44 (03) : 199 - 209
  • [7] EVALUATION OF OMALIZUMAB IN THE TREATMENT OF ALLERGIC RHINITIS
    SHAHZAD, Q.
    CANAVAN, B.
    CHEST, 2022, 161 (06) : 8A - 8A
  • [8] IgE plus B cells are scarce, but allergen-specific B cells with a memory phenotype circulate in patients with allergic rhinitis
    Wong, K. J.
    Timbrell, V.
    Xi, Y.
    Upham, J. W.
    Collins, A. M.
    Davies, J. M.
    ALLERGY, 2015, 70 (04) : 420 - 428
  • [9] Omalizumab is effective in the preseasonal treatment of seasonal allergic rhinitis
    Zhang, Yuan
    Xi, Lin
    Gao, Yunbo
    Huang, Yanran
    Cao, Feifei
    Xiong, Wei
    Wang, Chengshuo
    Zhang, Luo
    CLINICAL AND TRANSLATIONAL ALLERGY, 2022, 12 (01)
  • [10] Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously
    Kamin, Wolfgang
    Kopp, Matthias Volkmar
    Erdnuess, Frank
    Schauer, Uwe
    Zielen, Stefan
    Wahn, Ulrich
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2010, 21 (01) : E160 - E165